STING1 and glioma: Beyond radiation, and despite a lack of momentum from early-stage clinical trials (1), targeting the intratumor cGAS/STING axis with specific agonists of STING (e.g., analogs or derivatives of cGAMP) remains of interest in immunologically quiescent cancer types, such as gliomas (20).